Document is current
Any future updates will be listed below
-
Authors
Veneziani, Ana C. https://orcid.org/0000-0003-3980-034X
Lheureux, Stephanie
Millar, Douglas G. https://orcid.org/0000-0002-8640-7148
Dhani, Neesha
Colombo, Ilaria https://orcid.org/0000-0002-0602-8667
Madariaga, Ainhoa https://orcid.org/0000-0001-7166-9762
Soberanis Pina, Pamela
Atale, Swati
Chan, Yin-Ling
Lee, Joshua
Ramsahai, Janelle
Quintos, Judy
Wang, Lisa
Li, Xuan
Bowering, Valerie
Ohashi, Pam
Wang, Ben
Oza, Amit M. https://orcid.org/0000-0002-9510-8641
-
Funding
Funding for this research was provided by:
Ontario Institute for Cancer Research
Merck & Co., Inc. | Merck Sharp and Dohme
Immunovaccine
- License Information
-
More Information
Article History
Received: 8 March 2025
Accepted: 7 April 2026
First Online: 14 May 2026
Competing interests
: A.C.V.: Honoraria from AstraZeneca and Merck Sharp & Dhome; Consultancy/advisor role from Merck Sharp & Dhome outside the submitted work. S.L.: Institutional funding for clinical trials as PI from AstraZeneca, Merck Sharp & Dhome, Repare Therapeutics, Seagen, Schrodinger, GSK and Roche. Consultancy/advisor role from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dhome, AbbVie, Eisai, Zai Lab, Gilead, outside the submitted work. I.C.: declares institutional funding for clinical trials as PI from AstraZeneca, Merck Sharp & Dhome, Vivesto, Tolremo, Orion, Bayer, lncyte; consultancy/advisor role from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dhome, AbbVie, Biontech, lncyte, outside the submitted work. A.M.: Honoraria from AstraZeneca, AbbVie, Daichii Sankyo, Eisai, GSK, MSD, Lilly and Pharma. A.M.O.: PI and Steering Committees with AstraZeneca, GSK. Advisory to Abbvie, CEO in Ozmosis Research. The remaining authors declare no competing interests.
